Atlas Venture Life Science Advisors’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $214M | Hold |
4,896,462
| – | – | 32.26% | 1 |
|
|
2025
Q1 | $134M | Hold |
4,896,462
| – | – | 25.69% | 1 |
|
|
2024
Q4 | $197M | Hold |
4,896,462
| – | – | 24.03% | 1 |
|
|
2024
Q3 | $232M | Sell |
4,896,462
-453,960
| -8% | -$21.5M | 21.48% | 2 |
|
|
2024
Q2 | $160M | Sell |
5,350,422
-26,940
| -0.5% | -$804K | 16.82% | 2 |
|
|
2024
Q1 | $216M | Sell |
5,377,362
-480,900
| -8% | -$19.3M | 19.95% | 2 |
|
|
2023
Q4 | $149M | Hold |
5,858,262
| – | – | 17.76% | 1 |
|
|
2023
Q3 | $81.4M | Hold |
5,858,262
| – | – | 12.61% | 4 |
|
|
2023
Q2 | $135M | Hold |
5,858,262
| – | – | 16.76% | 2 |
|
|
2023
Q1 | $174M | Sell |
5,858,262
-126,474
| -2% | -$3.75M | 23.5% | 1 |
|
|
2022
Q4 | $149M | Sell |
5,984,736
-890,962
| -13% | -$22.2M | 17.99% | 2 |
|
|
2022
Q3 | $150M | Hold |
6,875,698
| – | – | 16.52% | 3 |
|
|
2022
Q2 | $135M | Hold |
6,875,698
| – | – | 22.63% | 2 |
|
|
2022
Q1 | $291M | Hold |
6,875,698
| – | – | 36.79% | 1 |
|
|
2021
Q4 | $437M | Buy |
+6,875,698
| New | +$437M | 40.09% | 1 |
|